

Biological Function of Nectin 4 in Ovarian Cancer

Adam B. Meyer, Kristin L.M. Boylan, and Amy P.N. Skubitz

Department of Laboratory Medicine and Pathology

Introduction

Ovarian Cancer Overview

- 5th leading cause of cancer death for women in the U.S.
- Most patients are diagnosed after metastasis, when survival rates are low
- Early diagnosis yields 93% five-year survival rate

Biomarkers and Nectin 4

• Biomarkers have different properties: early detection, clues to therapy effectiveness, and possible prognostic applications.

• Nectin 4 has been identified by the Skubitz lab as a possible biomarker for ovarian cancer. Nectins belong to a family of immunoglobulin-like proteins important in cell to cell adhesion.

• A study of 500 ovarian cancer tumors showed 48.6% stained for Nectin 4 while 53% of ovarian cancer blood samples tested positive. Nectin 4 also expressed in lung and breast cancer.




Image from DeRycke, (2010). S100A4 and Nectin 4 Biomarkers in Ovarian Cancer. University of Minnesota Dissertation.

Our hypothesis is that knocking down the expression of Nectin 4 will inhibit ovarian cancer cell function and metastasis.




Materials and Methods

The human ovarian cancer cell line NIH: OVCAR5 was used in these experiments.

Transfection- The cells were transfected with plasmids containing shRNA constructs TRCN0000061623(23) and TRCN0000061626(26) that targeted the Nectin 4 gene. shRNA's were purchased from the University of Minnesota Biomedical Genomics Center.

Testing for Knockdown:

1. RT-PCR was used to determine RNA levels of cells transfected with shRNA controls parental cells with known expression, and empty vector.
2. Flow cytometry was used to determine Nectin 4 protein levels on the surface of cells based on fluorescence when marked with an antibody.
3. MTT assays determined the metabolic proliferation of the cells.



Results




Figure 1. RT-PCR: The two shRNA inserts show definitive knockdown of the expression of Nectin 4 as compared to the Empty Vector samples.

- No insert NIH:OVCAR5 cell RNA without any plasmid added. Two different Empty Vector clones were used to compare to knockdowns. Empty vector cells are NIH:OVCAR5 with plasmid but no shRNA insert.
- shRNA samples include NIH:OVCAR5 + plasmid with the sequence targeting Nectin 4 present.
- MCF7 serve as positive control because of known Nectin 4 expression levels.
- Negative control has no RNA added to sample.




Figure 2. Flow Cytometry: Both of the shRNA inserts display knocked down overall expression of the Nectin 4 protein. shRNA #23 had 75.60% knockdown and #26 had 62.40% knockdown.

- Violet= Empty Vector, Pink = shRNA #26, Green = shRNA #23
- The x-axis shows the relative fluorescence levels of each sample while the y-axis displays the number of cells. Higher levels of fluorescence suggest more Nectin 4 expression.




Figure 3. MTT Proliferation Assay: Cells with knocked down Nectin 4 expression with both shRNA inserts show decreased metabolic activity compared to the empty vector.

- Assay is used to determine if Nectin 4 levels affect cell growth.
- Higher absorbance indicates higher metabolic activity in the cells of interest which translates into cell growth.

Summary and Future Directions

Summary

- Both shRNA's lead to knockdown in the expression of Nectin 4 RNA in ovarian cancer cells.
- Lower levels of Nectin 4 RNA in the cancer cells corresponds to a decrease in the Nectin 4 surface proteins.
- Presence of shRNA's promotes change in cell growth rates.
- Results suggest that Nectin 4 levels may affect cell proliferation.

Future Directions

- More analysis on both shRNA's #23 and #26 is needed in order to validate the consequence of knockdown of Nectin 4.
- Test additional shRNA's in similar experiments.
- Perform additional biological assays: scratch assay, to investigate the effect of Nectin 4 on cell movement, a spheroid assay to determine the rate at which cancer cells will form clusters based on the levels of Nectin 4 expression.
- Identifying other biomarkers that interact with Nectin 4.

References

1. DeRycke, M. S., Pambuccian, S. E., Gilks, C. B., Kalloger, S. E., Ghidouche, A., Lopez, M., Bliss, R.L., Geller, M.A., Argenta, P.A., Harrington, K.M., Skubitz, A.P.N. (2010). Nectin 4 overexpression in ovarian cancer tissues and serum. *American Journal of Clinical Pathology*, 134(5), 835-845.
2. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for Tumor Necrosis Factor-(alpha)-converting Enzyme (TACE)/ADAM-17. *J. Biol. Chem.* 2005; 280: 19543-50.
3. Nakanishi, H., & Takai, Y. (2004). Roles of nectins in cell adhesion, migration and polarization. *Biological Chemistry*, 385(10), 885-892.
4. Takano, Ishikawa, et. al. Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. *Cancer Res*, 2009 69;6694

A special thanks to the UROP program at the University of Minnesota for funding this project.